Exousia Bio, Inc. (LMMY)

Exousia Bio Cash Flow Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 30, 2025	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022
Net Income	-0.08	0.05	-0.03	-0.06	-0
Depreciation & Amortization	0	0.01	0.01	0.01	0
Asset Writedown & Restructuring Costs	0	0	-	-	-
Change in Accounts Receivable	0.02	0.01	-0.01	-	-
Change in Other Net Operating Assets	-0.08	-0.08	0.01	0	-
Operating Cash Flow	0.09	-0	-0.01	-0.04	-0
Long-Term Debt Issued	-	-	-	0	-
Total Debt Issued	-	-	-	0	0.03
Net Debt Issued (Repaid)	0.09	-	-	0	0.03
Issuance of Common Stock	22.05	0	-	0.03	0
Other Financing Activities	-0.18	-	0.01	0.01	0
Financing Cash Flow	21.96	0	0.01	0.04	0.03
Net Cash Flow	-0	-0	-0.01	-0	0.03
Levered Free Cash Flow	-	-	-0	-	-
Unlevered Free Cash Flow	-	-	-0	-	-
Change in Working Capital	0.11	-0.07	-0	0	-

Data Source: S&P Global Market Intelligence Last updated: Nov 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 7, 2026

Data Sources Report a data error